GlassScriptPhysician profile
Lillian Shade Shaffer
NPI 1154075752
$8,320.74
in general payments reported to CMS, 2019-2025
26 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,569 · 2023: $3,032 · 2024: $2,519 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,626 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,625.69 |
| Education | $126.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,135.98 | 2022-2025 | |
| Amgen INC. | $1,028.61 | 2022-2025 | Enbrel, Otezla, Avsola |
| Janssen Biotech, INC. | $956.19 | 2022-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $731.89 | 2022-2024 | Taltz |
| Ucb, INC. | $614.33 | 2022-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $518.55 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $425.20 | 2023-2025 | |
| Glaxosmithkline, LLC. | $419.29 | 2022-2025 | Benlysta |
| Horizon Therapeutics Plc | $339.97 | 2022-2023 | Krystexxa |
| Pfizer INC. | $211.71 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $129.14 | 2022-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $117.53 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $107.87 | 2024-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $100.48 | 2023 | |
| Sandoz INC. | $89.75 | 2023-2024 | Hyrimoz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $60.01 | 2023-2024 | Tymlos |
| Genentech USA, INC. | $45.40 | 2023 | Actemra |
| Fresenius Kabi USA, LLC | $44.78 | 2024 | Idacio |
| Sobi, INC | $42.47 | 2023-2024 | |
| Celltrion USA INC. | $41.33 | 2023 | Yuflyma |
| Organon LLC | $34.30 | 2023-2024 | Hadlima |
| Alexion Pharmaceuticals, INC. | $33.83 | 2024-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.79 | 2023 | Spevigo |
| Genzyme Corporation | $21.65 | 2025 | |
| Aurinia Pharma U.S., INC. | $21.22 | 2022 | |
| Acella Pharmaceuticals, LLC | $15.47 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.